The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator's latest study will use eye-tracking tools.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
The reason: Diovan.
A consumer survey will shape the regulator's position.
Canada's Office of the Privacy Commissioner says the search giant failed to protect what qualifies as sensitive user information.
A month after UBM Canon closed the B2B magazine, marketing firm Outcomes LLC announced its return to twice-a-year publication.
The agency says outlets need to rethink running ads that make false claims.
The Health Ministry alleges Novartis exaggerated advertising for its blood pressure drug Diovan.
Our year-end list captures the 10 that sparked heaviest interest.
Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.
An organ-donation campaign with a Brazilian football tie-in, and a UK managed-access company's series of documentary films, took top honors.
The drugmaker's latest financial plans could power it through mid-2015.
The FDA's Bad Ad group says the drugmaker misbranded its cholesterol drug during interviews on CNBC.
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
The regulator will study how teens perceive ads and if targeted media needs unique standards.
Growing client demand encouraged the agency to make its HCP content capabilities official.
The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
American Medical News' 55-year publishing run will come to a close this year, the AMA, its publisher, said today.
The company narrowed its second quarter loss, but said its national TV campaign is driving an uptick in consumer interest.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
FDA's Office of Prescription Drug Promotion issued an Untitled Letter over what it says are misleading copy and overstated efficacy claims online.
The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.
HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.
23andMe aired its first TV ad Monday, in a bid to build the audience for DNA sequencing.
The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.